Wild-type Sindbis virus (SV) shows promise as an oncolytic agent, although potential off-target replication is a safety concern. To remove possible pathology reflecting virus replication in liver, muscle, and/or hematopoietic cells, microRNA (miR)-response elements (MREs) to liver-specific miR122, muscle-specific miR133a and miR206, or hematopoietic-specific miR142-3p were inserted into the Sindbis viral genome. We compared the effectiveness of MREs in two distinct genomic locations and found better tissue-specific attenuation when they were inserted into the structural polyprotein coding region (up to 6000-fold selectivity with miR142-3p) rather than into the 3′ untranslated region (up to 850-fold with miR142-3p). While this degree of tissue-specific attenuation may be effective for relieving pathology in vivo, genetic instability of RNA viruses raises concerns over the mutation or loss of MREs conferring safety. Genetically modified SVs containing a reporter transgene, used as a surrogate for virus replication, mutated quickly in vitro, losing 50% transgene sequence within 6.2 passages. Using a shorter insert containing MREs but no transgene, complete genetic stability was observed over at least 10 passages. We conclude that SV may be genetically modified to improve clinical properties, but attention must be paid to ensure that genetic stability is sufficient for intended applications.
Get full access to this article
View all access options for this article.
References
1.
AdamsR.H., and BrownD.T. (1985). BHK cells expressing Sindbis virus-induced homologous interference allow the translation of nonstructural genes of superinfecting virus. J. Virol., 54, 351–357.
2.
AltmanhamamdzicS., et al. (1997). Expression of beta-galactosidase in mouse brain: utilization of a novel nonreplicative Sindbis virus vector as a neuronal gene delivery system. Gene Ther., 4, 815–822.
3.
ArbuthnotP., and ThompsonL.J. (2008). Harnessing the RNA interference pathway to advance treatment and prevention of hepatocellular carcinoma. World J. Gastroenterol., 14, 1670–1681.
4.
Assunção-MirandaI., BozzaM.T., and Da PoianA.T. (2010). Pro-inflammatory response resulting from sindbis virus infection of human macrophages: implications for the pathogenesis of viral arthritis. J. Med. Virol., 82, 164–174.
5.
BarrJ.N., and FearnsR. (2010). How RNA viruses maintain their genome integrity. J. Gen. Virol., 91, 1373–1387.
6.
Bazan-PeregrinoM., et al. (2008). Comparison of molecular strategies for breast cancer virotherapy using oncolytic adenovirus. Hum. Gene Ther., 19, 873–886.
7.
BrownB.D., et al. (2006). Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer. Nat. Med., 12, 585–591.
8.
BrownJ.D., et al. (2010). Ribosome “Skipping”: “Stop-Carry On” or “StopGo” translation recoding: expansion of decoding rules enriches gene expression. In Nucleic Acids and Molecular Biology. BujnickiJ.M., ed. (Springer, New York), pp. 101–121.
9.
CawoodR., et al. (2009). Use of tissue-specific microRNA to control pathology of wild-type adenovirus without attenuation of its ability to kill cancer cells. PLoS Pathog., 5, e1000440.
10.
CookS.H., and GriffinD.E. (2003). Luciferase imaging of neurotropic viral infection in intact animals. J. Virol., 77, 5333–5338.
11.
CooperP.D., et al. (1974). On the nature of poliovirus genetic recombinants. J. Gen. Virol., 23, 41–49.
12.
DavorenP., et al. (2008). Identification of suitable endogenous control genes for microRNA gene expression analysis in human breast cancer. BMC Mol. Biol., 9, 76.
13.
DicksonA.M., et al. (2012). Dephosphorylation of HuR protein during alphavirus infection is associated with HuR relocalization to the cytoplasm. J. Biol. Chem., 287, 36229–36238.
14.
DonnellyM.L.L., et al. (2001). Analysis of the aphthovirus 2A/2B polyprotein “cleavage” mechanism indicates not a proteolytic reaction, but a novel translational effect: a putative ribosomal “skip.”. J. Gen. Virol., 82, 1013–1025.
15.
DurbinR.K., and StollarV. (1986). Sequence-analysis of the E2 gene of a hyperglycosylated, host restricted mutant of sindbis virus and estimation of mutation-rate from frequency of revertants. Virology, 154, 135–143.
16.
EdgeR.E., et al. (2008). A let-7 microRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication. Mol. Ther., 16, 1437–1443.
17.
Esquela-KerscherA., and SlackF.J. (2006). Oncomirs—microRNAs with a role in cancer. Nat. Rev. Cancer, 6, 259–269.
18.
FrolovI., HardyR., and RiceC.M. (2001). Cis-acting RNA elements at the 5′ end of Sindbis virus genome RNA regulate minus- and plus-strand RNA synthesis. RNA, 7, 1638–1651.
19.
GiraldezA.J., et al. (2006). Zebrafish MiR-430 promotes deadenylation and clearance of maternal mRNAs. Science, 312, 75–79.
20.
GranotT., and MerueloD. (2012). The role of natural killer cells in combinatorial anti-cancer therapy using Sindbis viral vectors and irinotecan. Cancer Gene Ther., 19, 588–591.
21.
HahnC.S., et al. (1992). Infectious Sindbis virus transient expression vectors for studying antigen processing and presentation. Proc. Natl. Acad. Sci. USA, 89, 2679–2683.
22.
HeoJ., et al. (2013). Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat. Med., 19, 329–336.
23.
HuJ.C.C., et al. (2006). A phase I STUDY of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin. Cancer Res., 12, 6737–6747.
24.
HuangP.-Y., GuoJ.-H., and HwangL.-H. (2011). Oncolytic Sindbis virus targets tumors defective in the interferon response and induces significant bystander antitumor immunity in vivo. Mol. Ther., 20, 298–305.
25.
JanJ.-T., ChatterjeeS., and GriffinD.E. (2000). Sindbis virus entry into cells triggers apoptosis by activating sphingomyelinase, leading to the release of ceramide. J. Virol., 74, 6425–6432.
26.
JohnstonR.E., WanK., and BoseH.R. (1974). Homologous interference induced by sindbis virus. J. Virol., 14, 1076–1082.
27.
KellyE.J., and RussellS.J. (2009). MicroRNAs and the regulation of vector tropism. Mol. Ther., 17, 409–416.
28.
KellyE.J., et al. (2008). Engineering microRNA responsiveness to decrease virus pathogenicity. Nat. Med., 14, 1278–1283.
29.
KurkelaS., et al. (2004). Causative agent of pogosta disease isolated from blood and skin lesions. Emerg. Infect. Dis., 10, 889–894.
30.
KurkelaS., et al. (2005). Clinical and laboratory manifestations of Sindbis virus infection: prospective study, Finland, 2002–2003. J. Infect. Dis., 191, 1820–1829.
31.
LaineM., et al. (2000). Prolonged arthritis associated with Sindbis-related (Pogosta) virus infection. Rheumatology, 39, 1272–1274.
32.
LandgrafP., et al. (2007). A mammalian microRNA expression atlas based on small RNA library sequencing. Cell, 129, 1401–1414.
33.
LanniP., et al. (2013). The innovative evolution of cancer gene and cellular therapies. Cancer Gene Ther., 20, 141–149.
34.
LiuJ., et al. (2004). Argonaute2 is the catalytic engine of mammalian RNAi. Science, 305, 1437–1441.
35.
LuukkainenR., LaineM., and NirhamoJ. (2000). Chronic arthritis after Sindbis-related (Pogosta) virus infection. Scand. J. Rheumatol., 29, 399–400.
36.
MansourM., PaleseP., and ZamarinD. (2011). Oncolytic specificity of Newcastle disease virus is mediated by selectivity for apoptosis-resistant cells. J. Virol., 85, 6015–6023.
MathonnetG.R., et al. (2007). MicroRNA inhibition of translation initiation in vitro by targeting the cap-binding complex eIF4F. Science, 317, 1764–1767.
39.
PetersenC.P., et al. (2006). Short RNAs repress translation after initiation in mammalian cells. Mol. Cell, 21, 533–542.
40.
PosticB., et al. (1969). Two variants of Sindbis virus which differ in interferon induction and serum clearance. J. Infect. Dis., 120, 339.
41.
RajuR., SubramaniamS.V., and HajjouM. (1995). Genesis of sindbis virus by in-vivo recombination of nonreplicative rna precursors. J. Virol., 69, 7391–7401.
42.
RehwinkelJ.A.N., et al. (2005). A crucial role for GW182 and the DCP1:DCP2 decapping complex in miRNA-mediated gene silencing. RNA, 11, 1640–1647.
43.
RobertsM.S., et al. (2006). Naturally occurring viruses for the treatment of cancer. Discov. Med., 6, 217–222.
44.
RümenapfT., StraussE.G., and StraussJ.H. (1994). Subgenomic mRNA of Aura alphavirus is packaged into virions. J. Virol., 68, 56–62.
45.
RymanK.D., et al. (2000). Alpha/beta interferon protects adult mice from fatal Sindbis virus infection and is an important determinant of cell and tissue tropism. J. Virol., 74, 3366–3378.
46.
SaitoK., et al. (2009). Oncolytic virotherapy for oral squamous cell carcinoma using replication-competent viruses. Oral Oncol., 45, 1021–1027.
47.
SaneJ., et al. (2012). Prolonged Myalgia in Sindbis virus infection: case description and in vitro infection of myotubes and myoblasts. J. Infect. Dis., 206, 407–414.
48.
StraussJ.H., and STRAUSSE.G. (1994). The alphaviruses—gene-expression, replication, and evolution. Microbiol. Rev., 58, 491–562.
49.
ThomasJ.M., et al. (2003). Sindbis virus vectors designed to express a foreign protein as a cleavable component of the viral structural polyprotein. J. Virol., 77, 5598–5606.
50.
TsengJ.C., et al. (2004). Systemic tumor targeting and killing by Sindbis viral vectors. Nat. Biotechnol., 22, 70–77.
51.
TurellM.J. (1988). Horizontal and vertical transmission of viruses by insect by and tick vectors. In The Arboviruses: Epidemiology and Ecology, Volume 1. MonathT.P., ed. (CRC Press, Boca Raton, FL), pp 127–154.
52.
TurellM.J., LundstromJ.O., and NiklassonB. (1990). Transmission of Ockelbo virus by Aedes-Cinereus, Ae-Communis, and Ae-Excrucians (Diptera, Culicidae) collected in an enzootic area in central Sweden. J. Med. Entomol., 27, 266–268.
53.
UrbanowiczA., et al. (2005). Homologous crossovers among molecules of brome mosaic bromovirus RNA1 or RNA2 segments in vivo. J. Virol., 79, 5732–5742.
54.
VerheijeM.H., and RottierP.J.M. (2012). Retargeting of viruses to generate oncolytic agents. Adv. Virol., 2012, 798526.
55.
ZhangJ., FrolovI., and RussellS.J. (2004). Gene therapy for matignant glioma using Sindbis vectors expressing a fusogenic membrane glycoprotein. J. Gene. Med., 6, 1082–1091.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
